Ceftazidime

Ceftazidime is a bactericidal cephalosporin antibiotic that is resistant to most beta-lactamases and is effective against a broad spectrum of Gram-positive and Gram-negative bacteria. Bacteriology: Ceftazidime is bactericidal and works by inhibiting bacterial cell wall synthesis. In vitro, many pathogenic strains and isolates associated with hospital-acquired infections are sensitive to ceftazidime, including strains resistant to gentamicin and other aminoglycosides. It is highly stable against the beta-lactamases produced by most clinically important Gram-positive and Gram-negative bacteria and is therefore effective against many strains resistant to ampicillin and cephalothin. Ceftazidime shows a high degree of intrinsic activity in vitro. It is effective against most bacterial genera within a narrow minimum inhibitory concentration range, and its minimum inhibitory concentration also changes very little at different inoculation levels. In vitro, ceftazidime has been shown to be effective against the following bacteria: Gram-negative bacteria: Pseudomonas aeruginosa and other Pseudomonas species, Klebsiella pneumoniae and other Klebsiella species, Proteus mirabilis, Proteus vulgaris, Morganella morganii (formerly Morganella morganii), Proteus rettegeri, Providencia, Escherichia coli, Enterobacter, Citrinum, Serratia, Salmonella, Shigella, Yersinia enterocolitica, Pasteurella multocida, Acinetobacter, Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae (including ampicillin-resistant strains), Haemophilus parainfluenzae (including ampicillin-resistant strains). Gram-positive bacteria: Staphylococcus aureus (methicillin-susceptible strains), Staphylococcus epidermidis (methicillin-susceptible strains), Micrococcus, Streptococcus pyogenes (group A beta-hemolytic streptococci), Group B Streptococcus, Streptococcus pneumoniae, Streptococcus mitis, Streptococcus (except Enterococcus faecalis). Anaerobic strains: Peptococcus, Peptostreptococcus, Streptococcus, Propionibacterium, Clostridium perfringens, Clostridium, Bacteroides (many strains of B. fragilis are already resistant). In vitro, ceftazidime has no effect against methicillin-resistant Staphylococci, Enterococcus faecalis, many other enterococci, Listeria monocytogenes, Campylobacter species, and Clostridium difficile. In vitro, the efficacy of ceftazidime in combination with aminoglycosides is at least additive, and for some strains, there is a clear synergistic effect. This property is important in treating patients with neutropenia and fever.

The main ingredient of this product is ceftazidime, and its chemical name is (6R,7R)-7-[[(2-amino-4-thiazolyl)-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-3-methylpyridinium inner salt pentahydrate.

It is used for sepsis, lower respiratory tract infection, abdominal and biliary tract infection, complicated urinary tract infection and severe skin and soft tissue infection caused by sensitive Gram-negative bacilli. It is especially suitable for infections in immunocompromised patients caused by multiple drug-resistant Gram-negative bacilli, hospital-acquired infections, and central nervous system infections caused by Gram-negative bacilli or Pseudomonas aeruginosa.

Intravenous injection or intravenous drip. 1. For sepsis, lower respiratory tract infection, biliary tract infection, etc., 4-6g a day, divided into 2-3 intravenous drips or intravenous injections, the course of treatment is 10-14 days; 2. For urinary tract infection and severe skin and soft tissue infection, 2-4g a day, divided into 2 intravenous drips or intravenous injections, the course of treatment is 7-14 days. 3. For certain life-threatening infections, severe Pseudomonas aeruginosa infections and central nervous system infections, the dosage can be increased to 0.15-0.2g/kg a day, divided into 3 intravenous drips or intravenous injections. 4. The common dose for infants and young children is 30-100mg/kg a day, divided into 2-3 intravenous drips.

The adverse reactions of this product are rare and mild. A small number of patients may experience rash, itchy skin, drug fever; nausea, diarrhea, abdominal pain; mild phlebitis at the injection site; occasional transient increase in serum aminotransferase, blood urea nitrogen, and blood creatinine; leukopenia, thrombocytopenia, and eosinophilia, etc.

It is contraindicated in patients who are allergic to cephalosporin antibiotics.

Precautions during pregnancy and lactation: 1. No test has shown that ceftazidime can cause fetal malformation or teratogenicity. However, like all drugs, it should be used with caution in early pregnancy and the first few months of pregnancy. For pregnant women, it should be used only when the expected benefits outweigh the possible risks. 2. Low concentrations of ceftazidime can be excreted into breast milk through the mammary glands, so lactating women should be cautious when using ceftazidime.

1. This product is contraindicated with the following drugs: amikacin sulfate, gentamicin, kanamycin, tobramycin, neomycin, chlortetracycline hydrochloride, tetracycline hydrochloride, oxytetracycline hydrochloride, colistin sodium methanesulfonate, polymyxin B sulfate, erythromycin gluconate, erythromycin lactobionate, lincomycin, sulfisoxazole, aminophylline, soluble barbiturates, calcium chloride, calcium glucoheptonate, diphenhydramine hydrochloride and other antihistamines, lidocaine, norepinephrine, metaraminol, methylphenidate, succinylcholine, etc. Occasionally, it may also be contraindicated with the following drugs: penicillin, methicillin, hydrocortisone succinate, phenytoin sodium, prochlorperazine, vitamin B group and vitamin C, hydrolyzed protein. 2. The stability in sodium bicarbonate solution is better than that in other

Store below 25°C, away from light.

NCPC Hebei HUAMIN Pharmaceutical Co., Ltd.

• Founded in:

  2010-04-28

• Address:

  No. 98, Hainan Road, Shijiazhuang Economic and Technological Development Zone

• Tax NO.:

  91130182554463533P

• Registered Funds:

  1.450139 million yuan

• Website:

  Log in to view

• Email:

  Log in to view